OSAKA

in FOCus
Heritage For

The Future

Brought to you by the AAAS/Science Business OfficeAAAS is here – bringing educational infrastructure to the developing world.
AAAS is helping the Rwandan government rebuild its educational infrastructure as a way to help drive economic growth anddevelopment. By providing materials such as the Project 2061 Atlas of Science Literacy, lesson plans from Science NetLinks,
and access to Science digital libraries, AAAS is helping the people of Rwanda work toward a future built around science andtechnology. As a AAAS member your dues support these efforts. If you’re not yet a AAAS member, join us. Together we can makea difference.

To learn more, visit aaas.org/plusyou/rwanda

OSAK A IN F O CU S

CONTENTS
2-Heritage for the Future Osaka builds on its legacy in the biosciences
EXCELLENCE IN RESEARCH

4

Establishing a Comprehensive
Global Strategic Special Zone
in Osaka

6		

Unsurpassed Pedigree in Translational
Medicine

8		World-Class Interdisciplinary Research on
Imaging the Human Immune System

10'Brothers in Arms' in the Fight Against
Infectious Diseases

12

Critical Bridge For Drug Development

14"One plus one equals three and a little
more" at the National Cerebral and 		
Cardiovascular Center

page 415 Realizing the Potential for Life
Sciences in Osaka
INTEGRATING RESEARCH
AND BUSINESS

17

Dynamic and Evolutionary Research
on Protein Science

18	Excellence in Interdisciplinary Researchand Education
19

Pharmaceutical Approach to Alleviating
Human Disorders

20

Breaking the Mold: Changing Traditional
Views of Dentistry

21	Evolution from Molecular Biology to 			Atomic Biology

Page 15

21

Cognitive Neuroscience Robotics
at Osaka

22

Innovative Approaches to Neuroscienceand Microfluidics

23

Cancer Research at Osaka Prefecture
University© 2011 by The American Association for the Advancement of Science. All rights reserved.
18 February 20111

OSAK A IN F O CU S

Heritage for the Future
Osaka builds on its legacy
in the biosciences
Leaders of the city of Osaka’s academic, industry, andgovernment sectors are implementing ambitious plans
to make the Northern Osaka Biomedical Cluster oneof the top five bioscience regions worldwide within thenext 10 years. Reporting from Japan, Adarsh Sandhu
takes a closer look.

Osaka has been at the centerof Japan’s pharmaceuticals industry sincethe 17th century when the Doshomachi district was a hub for merchants trading herbal
medicines. The area has been an incubatorfor global companies like Takeda Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd,as well as the predecessor of Osaka University’s School of Medical Sciences.
“Osaka has a rich history of research in
the life sciences and is a base for major
pharmaceutical companies,” says former
president of Osaka University and immunologist Tadamitsu Kishimoto, currently aprofessor at the Graduate School of Frontier
Biosciences, Osaka University. “Biomedicine
has tremendous potential here. We want torealize the dream of former president Yuichi
Yamamura, who envisaged Northern Osaka
as an international hub for life sciences.”
Indeed, Osaka-based scientists havemade outstanding contributions to thelife sciences including the discovery by
Kishimoto of interleukin-6 (IL-6), a protein
governing the immune response. This led
to the development and commercializationof the IL-6-inhibiting drug, tocilizumab, forthe treatment of Castleman’s disease andrheumatoid arthritis. Kishimoto donates the
profits from the sale of tocilizumab to the2

Kishimoto Foundation to support research. “Iwant to contribute to nurturing the next generation of researchers in the life sciences,”says Kishimoto.
In the area of infectious diseases, the discovery of Vibrio parahaemolyticus—a bacterium that causes food poisoning—was
made at the university’s Research Institutefor Microbial Diseases (RIMD), and its brother institute, the Research Foundation forMicrobial Diseases (BIKEN), Japan’s largest
manufacturer of vaccines for diseases suchas chickenpox. Notably, scientists at RIMD
are also developing vaccines to fight malaria,
a so-called neglected disease, which affects
about 40 percent of the world’s population,
mostly in poorer countries.
The tradition of pioneering work in immunology, initiated by the late Yuichi Yamamura, is being continued by Osaka University’s
Kishimoto and by Shizuo Akira, director of
the Immunology Frontier Research Center(IFReC) whose research on Toll-like receptors, innate immunity, and viral recognition
has made him one of the most highly-citedimmunologists.
Breakthroughs have also been madein transplant surgery at Osaka University
Medical School, where surgeons performed
Japan’s first kidney transplant in 1964 andthe first simultaneous heart-lung transplantin 2009.
So what are the plans for Osaka’s returnto center stage?

Developing a Strategy
The core goals, which are contained in theso-called Osaka Bio Strategy, involve accelerating the development of new drugs
and medical devices; promoting constructive alliances between industry, academia,
and government throughout the Kansai area
(which includes the cities of Osaka, Kyoto,
and Kobe); and strengthening support for
venture capital companies (via the Osaka
Bio Fund’s ¥1.1 billion ($13 million) in capital
assets). The establishment of a Comprehensive Global Strategic Special Zone of theJapanese government is included, with twocore priority areas: the biomedical industry,and environment and new energy.
Participation is being sought from someof the world’s largest electronics, chemical,
and precision instrument companies, suchas Panasonic and Sharp, both of which areheadquartered in Osaka.
“The biomedical industry relies on medical
devices,” says Yasushi Sugimoto, director
general of the Department of Commerce,
Industry and Labor, Osaka Prefecture. “TheBrought to you by the AAAS/Science Business OfficeOSAK A IN F O CU S

Tada

Kansai region is Japan’s largest manufacturer of lithium ion batteries, generating ¥22
billion ($260 million) in revenue in 2009, andbatteries are a critical component of medical
equipment.”
To promote interdisciplinary and crosssector collaboration, the Osaka Bio Headquarters has been set up to bridge the gap
between research and commercial entities.
“The Bio Headquarters consists of members
from industry, academia, and government,”
says Kishimoto, president of the organization. “Members of this organization devise
plans to achieve our goals as part of the
Osaka Bio Strategy framework.”
To provide support for venture companies, the Osaka Bio Strategy includes thelaunch of a biotalent matching service catering to the human resource needs of startup companies.

CREDIT: (LEFT) © ISTOCKPHOTO.COM/SIMFO;(RIGHT) © ISTOCKPHOTO.COM/SHUNYUFAN

Promoting Research, Fostering
Business
To reduce both the time and cost of performing clinical trials, Osaka plans to makeavailable the expert services of institutions
such as the five hospitals of the Osaka
Prefectural Hospital Organization to thepharmaceutical industry. A clinical trials
website has also been set up, offering upto-date information about trial results. On
the policy side, a request has been madeby the Osaka Bio Headquarters to thecentral government and the Pharmaceutical and Medical Devices Agency to makepositive reforms to clinical trial regulations
and practices.
Knowledge of the properties of proteinsis extremely important for fundamental research on immunology, cancer treatment,
and drug discovery. Osaka is renowned for

mitsu Kishimotoits expertise in protein research, exemplified
by more than 50 years of research conducted at Osaka University’s Protein ResearchInstitute (PRI). Now, in an innovative development, the biomedical cluster launched
the Protein Mall in May 2009 as an open
access platform for drug discovery. It aims
to create a ‘drug development value chain’
to foster business opportunities based onprotein-related research.
Knowledge is essential, but collaborationis also critical to achieve Osaka’s goals.
As such, the Drug Seed Alliance Network
Japan—managed by the Osaka Chamber of Commerce and Industry—is actively
promoting partnerships between industries
both within Japan and overseas. Recent international agreements include memorandaof understanding signed with France, Australia, Belgium, and the BioBusiness Allianceof Minnesota.
A central and important facility in the
Northern Osaka Bio Cluster is the National
Institute of Biomedical Innovation (NIBIO),
which the government set up in 2005 toact as a stepping stone for commercializing
ideas from the laboratory and bringing theminto the clinic. Research at NIBIO ranges
from developing adjuvants for more effective vaccines to maintaining an ancestry
database of cynomolgus monkey colonies,
which is openly available to researchers.
The strength of Osaka’s expertise in life
sciences is based on decades of basic research conducted by imaginative and highly
motivated scientists, historically from within
Japan but now also from overseas. Shizuo
Akira, director of IFReC—launched in October 2007 as one of only five World PremierInstitutes chosen by the Japanese government—says that approximately 30 percent

of its principle investigators are foreign, arare situation in Japan, but made possible
through extensive support provided by IFReC staff for foreign scientists to help themovercome language and cultural barriers.

Looking to the Future
There are some disturbing trends among
young Japanese researchers that worry
their senior counterparts. “Youngsters are
reluctant to go overseas these days,” notes
Kishimoto. “It’s probably because Japanese
universities now offer world class research
environments. But research is not only
about equipment and clean rooms; meeting people from different backgrounds anddeveloping international networks is equally,
if not more, important.”
Only time will tell how these trends will affect Japan’s research prowess, but the newresearch programs have attracted manybright researchers from overseas, which
may compensate for the decreased willingness of Japanese scientists to travel internationally.
Osaka and the Kansai region have a lot
to offer the biomedical industry with new
projects in neuroscience, human-machineinterface research, cancer treatment, androbotic assistance in hospitals, all of whichbuild on the legacy of Osaka's pharmaceutical and electrical industries.
On balance, the important fact is that Osaka is still an energetic and forward-looking
location for pursuing research and businessin the biosciences.

Adarsh Sandhu holds joint professorships at
the Tokyo Institute of Technology and Toyohashi
University of Technology, Japan.

3

OSAK A IN F O CU S: Excellence in Research

Establishing a Comprehensive Global
Strategic Special Zone in OsakaT

he last halfof the 20th
century saw
Japan’s

automobile industry lead thenation to become a powerful
first-world economy. But this‘unipolar economic structure’has seen its day and therealities of the new millennium
dictate different approaches

To pull Japan out of the current economic
malaise, prominent members from academia,
industry, and government of Osaka Prefecture—
the heart of the Kansai region of Western Japan
incorporating the cities of Kyoto, Kobe, andNara—are devising new economic models
based on the historical strengths of the region’s
electronics, chemical, biomedical, and precision
instruments sectors. In particular, a strategy thatmakes full use of Osaka's current expertise in thebiomedical, and environment and new energy
industries will be the driving force, with a potential
economic upside of ¥700 billion ($8.3 billion).
The history of Osaka’s biomedical industry
goes back to the 17th century when the
Doshomachi district in Osaka City was thenational hub for the distribution of herbal
medicine and related materials. Centered on
Doshomachi, the Northern Osaka Biomedical
Cluster covers an area 40 km in diameter, andincludes university startups and pharmaceutical

4

Osaka: Traditional Enterprising Spirit Is Still Alive
companies as well as the world’s leading
research institutes. In recent years, the Northern
Osaka Biomedical Cluster has enjoyed areputation as one of the top biomedical clusters
in Japan.

government designation as a biomedical industry
area in this region, Osaka could act as a catalyst
to initiate the spread of ideas for life innovation
throughout the rest of Japan. Osaka will submit
a formal application in 2011.

Osaka Prefecture’s Proposal for theComprehensive Global StrategicSpecial Zone

The proposal includes:(1) Establishment of a PMDA (Pharmaceuticals
and Medical Devices Agency) office in the
Osaka region to accelerate the developmentof pharmaceuticals and medical devices, andresolve issues related to ‘drug-lag and devicelag’ (delays in drug and device development
and approval due to stringent government
regulations);(2) Extending the function of the National
Cerebral and Cardiovascular Center (NCVC)
by constructing new buildings to expand the
Research and Development Initiative Center andrelated medical clusters;(3) Setting up a Comprehensive Special Zone

One of the pillars of the Japanese government’s
strategy for economic growth is founded on avision of so-called Life Innovation for becoming
a leader in research and providing exceptional
health care. Now, Osaka Prefecture will help torealize this national goal by integrating the uniquepotential of Northern Osaka with the world-classbiomedical industries and abundance of highlyskilled employees available in this area.
In September 2010, Osaka proposed a draftof the Comprehensive Global Strategic Special
Zone to the national government. With a formal

CREDIT: © OSAKA CONVENTION & TOURISM BUREAU

for further economic growth.

Advertisement

CREDIT: (TOP PHOTOS) © OSAKA CONVENTION & TOURISM BUREAU

Midosuji: Main Business and Shopping Street in Downtown Osakabased on the achievements of Osaka University, NCVC, and the Osaka Medical Center for
Cancer and Cardiovascular Diseases to promoteclinical trials and treatment of cancer and cardiovascular diseases;(4) Setting up a multidisciplinary medical andwelfare robot demonstration experiment zone
by bringing together local small and medium
enterprises (SMEs) as well as global corporations such as Panasonic for the developmentof robot-assisted patient beds, automated drug
mixing for injections under aseptic conditions,and autonomous delivery robots for transporting
medical supplies and medicine;(5) Creation of a unified industry-academicgovernment approach to support the development of antibody and nucleic acid medicines
based on shared ‘good manufacturing practice’(GMP) facilities maintained at the Saito Life
Science Park in the Northern Osaka Biomedical
Cluster. In addition to contract-based manufacture of cutting-edge biomedical products, the
GMP facilities would strengthen the researchand development activities of startup companies
by offering consultation, development of humanresources, and collaborative research;(6) Increasing efforts to attract new vaccinerelated industries—the growth engines of medical industries—to form a strong foundation for
the research, development, and manufacture ofbiomedical products. This policy takes advantage of Osaka University’s research institutes—
the Immunology Frontier Research Center, theResearch Institute for Microbial Diseases, andthe Institute for Protein Research—and the National Institute of Biomedical Innovation (NIBIO),
located in the Saito Life Science Park, all world
leaders in vaccine research.

Osaka's Bay Area as the New
Administrative Center

New Energy and Biomedicine
The Comprehensive Global Strategic Special
Zone also includes an area that addresses
environmental and new energy industries.
Osaka Prefecture hopes that the inclusionof academic and industrial initiatives on
new energy as well as the integration of
biotechnology will provide the impetus to
improve Osaka’s economic potential and create
a positive ripple effect throughout the rest ofJapan.
Osaka has a rich history of innovative contributions to the development of new energy
resources. For example, Osaka is recognizedglobally for manufacturing 34 percent of theworld’s supply of lithium ion batteries. In thearea of photovoltaics, industries in Osaka
manufacture 11 percent of solar cells soldworldwide.
The Research and Development Initiative
for Scientific Innovation of New Generation
Batteries, or RISING, program aims tounderstand the nature of the chemical
reactions governing the lifespan of lithium ion
batteries, and develop batteries with five times
greater energy storage capacity than current
technology. Future applications include not
only automobiles, but also portable devices for
improved health care.
Taking the lead in the development andadoption of new energy technologies, Osaka
will be hosting the Osaka New Energy Forum2011, scheduled for 24–26 March, at the
Osaka International Convention Center. Chairedby Osaka Governor Toru Hashimoto, the themeof the conference will be to review the roleof electric vehicles in society. The organizers
expect about 10,000 participants at the event.

Panasonic's In-Hospital Delivery
Robot, "HOSPI"

MORE INFOThe Osaka New Energy Forumwww2.convention.co.jp/oneforum/en/

5

OSAK A IN F O CU S: Excellence in Research

Unsurpassed Pedigree in Translational Medicine
Osaka University Medical School and affiliated facilities set the example for a comprehensive approach towards taking cuttingedge research from the laboratory to the clinic, and into the home.

Osaka University Medical School

6

Toshio Hiranoand Hirano as well as Charles Dinarello, who
discovered IL-1.
“The discovery of IL-6 and more recent clarification of the signal pathways involving Toll-likereceptors by Shizuo Akira of the Immunology
Frontier Research Center are two examples of
the research that have made Osaka University aworld-class center for immunology,” says Hirano.
The Medical School also has world-classmedical imaging resources including an ultrahighresolution semiconductor positron emission
tomography (PET) system commissioned in July
2010, the world’s first permanent magnet PET/MRI (magnetic resonance imaging), a real-time
positron imaging system for monitoring the kinetics of drugs inside the body, a compact cyclotron
system for the generation of radioisotopes andlabeled compounds, and a 11.7 Tesla MRI facility
at the Graduate School of Frontier Biosciences.
In new developments, a 7 Tesla functional-MRI
system will be available at the National Institute ofInformation and Communications Technology on
the campus.
“Osaka will use these imaging facilities to focus
on the treatment of degenerative diseases—suchas Alzheimer’s disease—and malignant diseases,” says Hirano. “In addition, we are working
on clarifying the mechanisms governing the onset

Robotic Arm Operated byElectrocorticogram

Masahiro Fukuzawa
of other ailments such as cardiovascular andautoimmune diseases in order to develop better
drugs and treatments.”
The Osaka University Medical School is also
recognized for pioneering transplant surgery, performed at Osaka University Hospital, starting withJapan’s first kidney transplant in 1964, the firstheart transplant in 1999 (following the 1997 passage of new legislation on organ transplants by
the Japanese government allowing the harvestof organs from brain dead patients), and the firstsimultaneous heart-lung transplant in 2009.
Osaka University Hospital is the largest hospitalin the Kansai region. “We have about 2,000
staff, including 800 doctors,” says Masahiro
Fukuzawa, director of the hospital. “In 2009,
we had about 620,000 outpatients, 340,000
inpatients, and performed 8,700 operations. We
are an information technology-oriented hospital,
with a heliport on the roof, and a world-classtrauma and acute critical care center.”
In 2008 an oncology center was set up at thehospital where cancer surgery is performed andclinical research is carried out on different therapy
modalities, including drugs, radiation, and relaxation. Furthermore, as part of the Cancer Professional Training Program first launched in 2007,
education courses for patients and the generalpublic were initiated on these same therapies.
At the heart center, established in 2007,
clinicians treat severe heart failure andintravascular disorders as well as perform heart
surgery. “We are also developing advanced
medical treatments for cancer and for partialorgan transplants,” says Fukuzawa.
The hospital collaborates with internal
research groups including the Medical Center
for Translational Research (MTR), set up in

CREDIT: (BOTTOM RIGHT) THIS WORK WAS SUPPORTED BY THE STRATEGICRESEARCH PROGRAM FOR BRAIN SCIENCES OF MEXT.

The Medical School at Osaka University,a part of the Faculty of Medicine within
the Graduate School of Medicine, isthe oldest in Japan, with roots goingback to the Tekijuku school established in 1838
by Ogata Koan, pioneer of Western medicine
in Japan, and the first person in Japan toencourage a systematic approach to smallpox
vaccination.
“Our medical school has played a pivotal role
not only in the development of medicine in thiscountry but also in the growth of Osaka University as a whole,” says Toshio Hirano, dean of
the Graduate School of Medicine.
In the early days the Medical School was
renowned for the treatment of infectious diseases
such as smallpox and pulmonary tuberculosis. A
high standard of both innovative treatments andcutting-edge research continues today.
The Medical School later evolved into an
immunology hub as the result of breakthroughs
including the discovery of interleukin-6 (IL6)—a key immune stimulatory molecule—by
Tadamitsu Kishimoto and Toshio Hirano. This led
to the development of Japan’s first humanizedmonoclonal antibody therapy, tocilizumab, whichblocks the action of IL-6 and is used to treat
rheumatoid arthritis, joint inflammation, andCastleman’s disease.
Recently, the impact of the discovery of IL-6
and tocilizumab was acknowledged by the joint
award of the 2009 Crafoord Prize by the Royal
Swedish Academy of Science to Kishimoto

Advertisement

Toshiki Yoshimine

Akira Myoui

2002 to conduct research on topics including
regenerative medicine, robotic surgery, anddiagnostic imaging.
“Being located within the hospital enables us tohave first-hand interaction with the patients andclinicians,” says Toshiki Yoshimine, director of
the MTR. Patient confidentiality and protection isa top priority. “Out of an abundance of caution
we have established an ethics committee withwhom we consult on decisions about exploratory
clinical trials,” says Yoshimine.
Innovative work is being done in tissue regeneration using a patient’s own cells. Examples
include the use of myoblast sheets produced
from femoral muscle for the treatment of cardiomyopathy and engineered cell sheets composedof oral mucosal epithelium for corneal reconstruction. “With this technology there is no risk of
immunological rejection,” says MTR Vice Director
Akira Myoui.
“One of our most challenging projects is on thebrain-machine interface,” says Yoshimine. “We
are developing technologies to gauge humanintent based only on brain activity as an alternative means of communication for people withsevere motor impairments, such as ALS [Amyotrophic Lateral Sclerosis].” In recent trials, clinicalresearchers implanted electrodes directly onto
the surface of the brains of patients with epilepsy
or intractable pain in an attempt to treat these
diseases. Analysis of information-based brain
responses to simple grasp, pinch, and releasehand movements in these patients has enabled
them to control robots in real time. “Theseare very promising results,” says Yoshimine.
“Ultimately we want to develop a commercial,fully-wireless implantable system.”
Kazutomo Ohashi is head of the Divisionof Health Sciences at the Medical School. “OurHaruo Sugiyama

division is unique in Japan,” says Ohashi. “Ourstudents have backgrounds in nursing science and medical technology science. They are
studying in one of our three unique interdisciplinary programs, which are based on informatics,
mechanics, and life sciences.”
Yuko Ohno and Kenji Yamada are in
the Department of Robotics and Design for
Innovative Healthcare. “This department reflects
a collaboration between Osaka University and therobotics center at Panasonic Corporation,” says
Ohno. “Our nurses are working with robotics
experts to develop a database of how robots
could operate in hospitals.” One exciting project
being conducted at the Osaka University, incollaboration with other groups, is looking at
the potential of robotic beds, which will enable
patients to move from the bed to a wheelchairwithout human assistance. “This is a uniqueexperiment fusing engineering and nursing,” says
Yamada. “Also, working directly with industry will
enable rapid translation to actual applications in
the future.”
Immunology is another strong area of researchat the Division of Health Sciences led by Haruo
Sugiyama, developer of the WT1 (Wilms’ Tumor
Gene 1) peptide cancer vaccine. “We completed
phase one clinical trials at Osaka University
Hospital in 2002,” says Sugiyama. “We are
now pursuing phase 2 trials.” The WT1 gene ishighly expressed in both hematopoietic and solid
tumors. Sugiyama demonstrated that WT1 plays
an oncogenic role via its antiapoptotic function
and promotion of cell motility, and is thus a promising target for cancer therapy.
The third major new program at the Division of
Health Sciences is the Center for Twin Research,
led by Kazuo Hayakawa. “This is the first centerin Japan to focus on collecting data from twins

Kazuo Hayakawa

Kenji Yamada and Yuko Ohno

Osaka University Hospital
aged 65 to 100 to clarify the effects of genetics
and environment on health,” says Hayakawa.
“For example, why would one twin die at 70 andthe other at 100?”
The twin research project, which is one of
the Japanese government’s ‘Life Innovation’programs, will assess 1,000 twins separated intheir youth who went on to live in different environments. Researchers will use NMR, PET, andother similar methods to examine the subjects.
Results will be stored in a biobank accessible toscientists worldwide. “We want to use the resultsfor preventative medicine, and perhaps even foranti-aging strategies,” says Hayakawa.

MORE INFOOsaka University Graduate Schoolof Medicine
www.med.osaka-u.ac.jp/index-e.html

Osaka University Hospital
www.hosp.med.osaka-u.ac.jp/

Osaka University Hospital Medical Center
for Translational Researchwww.hp-mctr.med.osaka-u.ac.jp/

Kazutomo Ohashi

A Laboratory at Osaka University
Medical School

Graduate School of Medicine,
Division of Health Sciencessahswww.med.osaka-u.ac.jp/eng/welcome.html

7

OSAK A IN F O CU S: Excellence in Research

World-Class Interdisciplinary Research on Imaging the
Human Immune System
Scientists at the Immunology Frontier Research Center (IFReC) of Osaka University are using a large-scale, interdisciplinary
approach to spatiotemporal imaging of the body’s immune system.

T

IFReC Research Building

8

Shizuo Akira
a conscious effort to establish an international
center,” says Akira. “In fact, five of the principle
investigators are from overseas.”
In fiscal year 2009, the WPI-IFReC acquired
funding totaling ¥1.35 billion ($15.9 million) and
its researchers published 229 articles—statistics
that underscore the high level of research activity
at the center.
Takao Kodama is administrative director at
WPI-IFReC, with responsibilities that include
supporting overseas researchers living in Japan.
“One of the unique administrative aspects ofthis WPI-IFReC research project is that we deal
directly with MEXT and our decision-making
process is top-down,” says Kodama. “We do
not have to holdunnecessary faculty meetings. This
enables a highly
efficient administrative process. In
addition, the WPIIFReC administration has made a
conscious effort toenable a smoothtransition for overseas researchers
moving to Japan,
and to offer
them convenienthousing near thecampus as well as

Cevayir Coban
assistance with preparing applications for grants
and other such matters.”“I am quite satisfied with the support we
receive from the administration staff,” says
Nicholas Smith, a principle investigator from
Australia, who was attracted to the worldrenowned immunology research program at
Osaka.
“English is the de facto language for both administration and research,” says Cevayir Coban,a principle investigator who moved to Osaka fromthe United States and the recipient of a $100,000
research grant from the Bill and Melinda Gates
Foundation. “The Japanese language is not a
hurdle for conducting research here.”
In addition to partnerships within Japan, WPIIFReC is collaborating with overseas research
institutions, including the National Institutesof Health; the University of California, San
Francisco; the California Institute of Technology;
Harvard University; New York University; Stanford
University; POSTECH in Korea; and the Indian
Institute of Science Education and Research in
Bhopal, India.
The research facilities of WPI-IFReC include
the 10-story, 10,000 m2 Integrated Life Sciencebuilding completed in June 2009, the four-story
2,500 m2 Animal Resource Center, and a newnine-story 8,000 m2 research space—scheduled
for completion in March 2011—connected to themain research building. Notably, the WPI-IFReC
is strategically located adjacent to the ResearchInstitute for Microbial Diseases (RIMD) and the

CREDIT: (BOTTOM) BY J. SAKANOUE

he Osaka University Immunology
Frontier Research Center (IFReC) was
selected in 2007 by the Japanese
Ministry of Education, Culture, Sports,
Science and Technology (MEXT) as one of only
five coveted WPI (World Premier International)
research centers.
“IFReC is a unique interdisciplinary research
center built on the foundations of our pioneering
work in immunology,” says Shizuo Akira,director of WPI-IFReC. “We are taking aspatiotemporal approach to obtain a complete
picture of the immune response in the humanbody. Our projects are a fusion of expertisein immunology, imaging technology, andbioinformatics.”
One of the ultimate goals of the research at
WPI-IFReC is to craft methods for controllingthe dynamics of immune cells for the development of tailor-made vaccines and immunotherapy treatments.
Research at WPI-IFReC is being conducted byapproximately 170 specialists of whom one-third
are non-Japanese researchers. “We have made

Advertisement“Clarifying the mechanisms of the innate immune response is important for thedevelopment of strategies for the treatment and prevention of malaria.”

Institute for Protein Research (IPR), forming a
massive interdisciplinary research complex.
WPI-IFReC is keen to recruit highly motivatedpostdoctoral researchers from overseas, andoffers WPI-IFReC Kishimoto Foundation Fellowships of about ¥4,400,000 ($52,600) per year.
The Kishimoto Foundation was set up in 2008 in
honor of Tadamitsu Kishimoto, ex-president of
Osaka University.
To enhance its global visibility, WPI-IFReC organizes a wide range of international workshops
and symposia to encourage further research andcollaboration. “We organize a Winter School withcolleagues in Singapore,” says Akira. “Postdoctoral researchers from overseas can apply for the
40 or so places available. The next Winter School
is on January 16–21, 2012 and will be held on
Awaji Island, in the Seto Inland Sea.”
As part of its outreach programs, WPI-IFReC
holds regular science cafés in the Osaka city
center. “These are very popular,” says Kodama.
“We have many regulars who attend.”
In vivo imaging of cell movement is one of
the central themes of research at WPI-IFReC.
Principle investigator Masaru Ishii is an expert
on intravital two-photon imaging of bone tissue
in vivo. Ishii recently discovered a method forregulating the mechanism governing osteoclastogenesis by controlling the dynamics of movementof osteoclast precursors between blood andendosteum. “The significance of our research isthat we perform experiments in living animals,
thereby giving us a real-life view of the dynamics
of osteoclast cells, which are involved in bone
tissue destruction and resorption,” says Ishii,
who is one of the many physician-scientists at
WPI-IFReC.
Two of the major goals of Ishii’s research are tofind alternatives to bisphosphonates and vitamins
for the treatment of bone resorptive disorders,
and to develop in vivo visualization techniques
to clarify the migration and differentiation of hematopoietic stem cells, which give rise to all bonemarrow-derived cell types in the blood.
“Our discovery that sphingosine-1-phosphate
regulates the migration of osteoclast precursors
is an important advance for the treatment of

Nicholas Smithrheumatoid arthritis and osteoporosis,” says Ishii.
“Bone biology will become even more important as the number of aged people increases
worldwide.”
Label-free imaging offers several advantages
over widely-used fluorescent techniques, including a simpler protocol and elimination of spurious
data related to nonspecific interactions between
labels and targets. At WPI-IFReC, Smith focuseson label-free imaging of living cells using optical
Raman scattering. “We record light scatteredfrom a cell scanned with 532 nm laser light,
which resonates with molecular states in a cell,”says Smith. “The challenge is detecting extremely
low-intensity scattered light. Our setup enables
the extraction of well-defined 3D images ofmolecular changes in cells.”
Smith is also pursuing the use of nanoparticles
to enhance the local light field around these particles, allowing for ultrahigh-resolution laser imaging and even real-time modification of cells. For
example, particles can be heated using laser lightto potentially ablate subcellular compartments, orthe laser beam itself can induce changes in thecell directly.
“Recently, we controlled the beating ofheart muscles using pulsed laser irradiation,”says Smith. “This effect is due to the releaseof calcium ions during laser irradiation, anddemonstrates how lasers are now being used in
new ways for in situ measurement or control ofbiological functions.”
Vaccine development to prevent malaria is

Masaru Ishii
another high-priority research area at WPI-IFReC.
“Clarifying the mechanisms of the innate immune
response—that is the body’s natural resistanceto the Plasmodium parasite—is important for thedevelopment of strategies for the treatment andprevention of malaria,” says Coban.
Coban is using mouse models of malaria todevelop new vaccines to fight the disease, inparticular DNA vaccines incorporating adjuvantsfor efficient immunogenicity. Specifically, Coban
is studying hemozoin—a pigment produced by
the malaria parasites as a byproduct of blood
digestion and an essential compound for theirsurvival—for use as an endogenous vaccine adjuvant against malaria. “We found that hemozoin
binds directly to TLR9 [Toll-like receptor 9] andactivates it,” says Coban. “Synthetic hemozoin
acts as an adjuvant in a canine anti-allergenvaccine, and we concluded that hemozoin affects immune responses to malaria infection.”
These results have important implications for thedevelopment of vaccine adjuvants for malaria
treatment in humans.
The WPI-IFReC is aiming to break new
ground in immunological research, and its staff
are deeply committed to creating a unique andhighly-imaginative research base in Japan.

MORE INFO
Immunology Frontier Research Center(IFReC), Osaka University
www.ifrec.osaka-u.ac.jp/index-e.php

9OSAK A IN F O CU S: Excellence in Research'Brothers in Arms' in the Fight Against Infectious Diseases
RIMD and BIKEN are two of Osaka University’s premier institutes with a common mission to eradicate infectious diseases.

The Research Institute for Microbial
Diseases (RIMD) and The Research
Foundation for Microbial Diseasesof Osaka University (BIKEN) were
established as ‘brother’ organizations in 1934
following a donation from Gendo Yamaguchi,
an Osaka entrepreneur.
“Our roots can be traced back to 1934and microbiologist Tenji Taniguchi, who wasconvinced of the need for a counterpart to theInstitute of Infectious Diseases at Tokyo Imperial
University, now the University of Tokyo,” says
Shigeharu Ueda, director of BIKEN. Taniguchi
strongly urged the head of the Osaka Imperial
University to set up an institute in Osaka “topursue basic and clinical medicine.” Both RIMD
and BIKEN were established using funds from
Yamaguchi, who was extremely impressed with
Taniguchi’s ambitious suggestions. Profits fromBIKEN are used to fund research at RIMD in addition to supporting other academic research on
microbial diseases.
RIMD conducts research on microbiology,
oncology, and molecular biology. “We have morethan 200 researchers here,” says Hitoshi
Kikutani, RIMD director. Researchers at RIMD
have made significant contributions to the life
sciences, examples being the discovery of cellfusion, which led to the development of monoclonal antibodies—important tools for drug discovery and basic research—and the discovery of
the bacteria known as Vibrio parahaemolyticus,
which causes food poisoning.
Importantly, RIMD participates in international
research and maintains collaborative research
centers with the support of the Japanese
government, including the Thailand-Japan
Research Collaboration Center on Emerging
and Re-emerging Infections (RCC-ERI), which
was set up in Bangkok in 2005. “The RCC-ERI
is a partnership with Thailand’s National Instituteof Health,” says Kikutani. “The facilities include
biosafety level 3 laboratories for research on

10

Shigeharu Ueda
HIV/AIDS and avian flu.”
Building on its success with RCC-ERI, in2010 RIMD was selected to be a member of
the Japan Initiative for Global Research Network
on Infectious Diseases (J-GRID), a five-year
program launched by the Ministry of Education,
Culture, Sports, Science and Technology (MEXT)
as a successor to the RCC-ERI with the goalof establishing long-term research activities via
further development of the RCC-ERI initiative. As
one of activities of this program, RIMD set up the
Mahidol-Osaka Center for Infectious Diseases(MOCID) at Mohidol University in Thailand in
2010. Specific objectives include finding treatment solutions for bacterial infections, HIV/AIDS,
and mosquito-borne infectious diseases throughcollaborations with infectious disease researchorganizations from other countries.
BIKEN is known internationally as Japan’slargest manufacturer of vaccines, and in line withgovernment reforms of nonprofit foundations,
it was restructured into a general incorporated
foundation in April 2010. “The vaccines wemanufacture are developed and produced
based on the fundamental research conducted
at RIMD,” says Ueda. “Recently, we were at thefront line in the fight against the pandemic H1N1
influenza virus and produced 5 million doses ofthe vaccine.”
Historically, BIKEN has been at the forefront

Hitoshi Kikutaniof the development of vaccines. Shortly after
the construction of the Ishibashi production
plant in 1935, BIKEN was given approval for the
manufacture of seven vaccines, including thosefor cholera and pertussis. Then, at the end ofWorld War II in 1945, BIKEN played a central role
in restoring the health of the Japanese people
by supplying large quantities of vaccines to fightcholera and smallpox. In 1952, BIKEN received
approval for the first made-in-Japan influenza
virus vaccine, followed by another first in 1961
for inactivated polio vaccine. Between 1965 and1970, BIKEN began manufacturing several formsof the measles vaccine, as well as a vaccine
for chickenpox. Just recently, in 2009, BIKEN
obtained approval for the manufacture of cell
culture-derived Japanese encephalitis vaccine.
“Cell cultured production is faster than procedures using eggs,” says Ueda. “The rapid spreadof diseases requires equally rapid responses. We
continuously strive to improve the development
and manufacture of vaccines.”
BIKEN may be an unsung hero in the fightagainst measles, having supplied the CAM70
vaccine to UNICEF. “Over ten years we supplied
about 200 million doses of CAM70,” says Ueda.
“This vaccine eliminated measles in Brazil. In
cooperation with JICA, the Japan International
Cooperation Agency, we helped Indonesia to set
up a manufacturing plant in Bandon, which isAdvertisement“Preventative medicine not only prevents the spread of disease but also reduces
the cost of national health care budgets.”

Malaria Testing Clinic
being used to manufacture CAM70 for export.”
Ueda admits that, despite the success of
CAM70, Japan still has not eliminated measles
due to a lack of complete acceptance of vaccines by young mothers. In the 1990s, BIKEN
transferred the know-how for the production ofchickenpox vaccines to the U.S. company Merck& Co., Inc. “Our vaccines have had a dramaticeffect on reducing chickenpox in the USA,” says
Ueda. “Preventative medicine not only prevents
the spread of disease but also reduces the costof national health care budgets. For BIKEN thepatent royalties from the vaccine for chickenpox
raised about ¥10 billion ($120 million) over ten
years, which was used to fund construction of a

Bornavirus

Keizo Tomonaga
new production plant.” In addition to the manufacture of vaccines, BIKEN also offers JICA training courses on infectious disease-related topics
approved by the World Health Organization.
Plans for the future include a major effort todevelop a malaria vaccine. “About 40 percent of
the world’s population lives in malaria-endemic
regions,” says Ueda. “We have initiated clinical
trials in Uganda for a malaria vaccine based on
the serine repeat antigen [SERA], a protein produced by the Plasmodium falciparum parasite,which is responsible for malaria.” Phase 1 trials
on vaccine safety were completed in December
2010. “Malaria is present only in the jungles ofAsia, but is everywhere in Africa,” says Ueda.
“About one million people die annually due tobrain malaria alone.” RIMD researchers are administrating the SE36 SERA vaccine in Uganda.
If approval is obtained, the vaccine will be manufactured at the Kanonji Institute of BIKEN, which
complies with strict international good manufacturing practice (GMP) standards.
In a new initiative, BIKEN is funding a chair
at RIMD to conduct research on dengue fever
starting in April 2011, and will be building alaboratory at MOCID.
A recent highlight of research at RIMD isthe discovery by Keizo Tomonaga and colleagues of DNA remnants of the nonretroviralbornavirus in mammalian genomes, including

humans. These endogenous viruses are socalled because they become integrated into the
genome of their host. “About eight percent of
the human genome is known to be composed ofendogenous viruses,” says Tomonaga. “But this
discovery was a case of serendipity.”
Bornaviruses cause neurological disorders inhorses. The name originates from the city of Borna in Germany, where outbreaks of the disease
were recorded to have occurred in 1885.
These findings imply that RNA viruses are
extremely old, with analysis suggesting thatbornaviruses have coexisted with primates forabout 40 million years.
“This report generated a lot of international
news coverage,” says Tomonaga. “In addition tonewspaper reporters, the American Museum of
Natural History contacted us about this discovery, and there is now a panel on display about
so-called fossil viruses at the museum.”

MORE INFO
Research Institute for Microbial
Diseases (RIMD)
www.biken.osaka-u.ac.jp/e/Research Foundation for Microbial
Diseases of Osaka University (BIKEN)
www.biken.or.jp/english/index.html

11

OSAK A IN F O CU S: Excellence in Research

Critical Bridge For Drug Development
Located in the Saito Life Science Park in Northern Osaka, The National Institute of Biomedical Innovation fulfils the critical roleof bridging the gap between basic research on drug discovery and drug development for commercialization.

N“

IBIO was set up by the Japanese government in April 2005
to act as a mediator between
basic research at universities
and commercialization by industrial corporations,” says Koichi Yamanishi, director generalof The National Institute of Biomedical Innovation(NIBIO). “Our institute plays a unique role in thedevelopment of drugs in this country.”
The institute’s three main functions are
conducting basic research, sharing biologicalresources, and funding research. Furthermore,
NIBIO’s Tsukuba Primate Research Center houses a large scale breeding colony of about 2,000monkeys—mostly cynomolgus macaques—
whose family history has been recorded for over
30 years, making it a valuable resource available
to researchers in pharmaceuticals research anddevelopment.
NIBIO’s budget for fiscal 2010 is ¥11.20 billion($133 million). “We actively support innovativeideas,” says Yamanishi. “It is not widely known
that NIBIO funded Shinya Yamanaka during theearly stages of his research on induced pluripotent stem (iPS) cells.” NIBIO also funds venturecompanies and offers grants and consultation
on so-called orphan products—pharmaceuticals
and medical devices for rare diseases—whichlarge corporations can be reluctant to invest in
because of the small numbers of affected patients and consequently limitations in recouping
development costs.
In spite of the relatively small size of NIBIO,
statistics underscore the significant scientific contributions of its 50 full-time researchers and theirgroups. For example, in fiscal year 2008 each
NIBIO researcher received on average ¥16 million($190,000) from competitive grants—the highest
grants per person ratio for researchers at Japan’s
approximately 30 independent administration
agencies. Furthermore, in 2009 each researcher
published an average of three peer-reviewed
papers—about twice the number in 2005.

12

Koichi Yamanishi
In April 2010, NIBIO started its second phaseof research (scheduled for completion in 2014)
focusing on three areas:(1) Next generation vaccines with an emphasison the development and understanding of adjuvants to enhance efficacy;(2) Drug toxicity testing systems including a
new method to induce differentiation in a variety
of stem cell types;(3) Treatment of intractable or rare diseases byanalyzing the molecular mechanisms governingthese disorders and the development of relevant
technologies for diagnosis and treatment.
Since 2008, NIBIO has been working on two
industry-academia-government collaborative
projects based on Super Special Consortia
programs for the development of cutting-edge
medical care. They are the Next Generation
Infectious Disease Vaccine Innovation Program,and the Development of a Novel Drug Toxicity
Testing System using human iPS cells. Notably,
these projects were two of only 24 suchprograms approved by the government.
“The development of a drug takes about 15
to 20 years,” says Yamanishi. “NIBIO was set up
only five years ago, and during the second phaseof research I want to push for actual commercialization of some of the drugs being studied in
our projects.” NIBIO also works with international groups including Cambridge
University (on bioinformatics), as well
as Peru and the Solomon Islands(on medicinal plants).

Medicinal Plant Research
Nobuo Kawahara is director of
the Research Center for Medicinal
Plant Resources (RCMPR). “OurTetsuji Naka
center is the only comprehensive research facility
in Japan conducting research on the cultivation
and biochemical analysis of medicinal plants,”
says Kawahara.
The center cultivates and preserves morethan 4,000 species and groups of medicinal
plants, and supplies seeds and advice to otherresearch institutes. Notably, only 12 percent of
the medicinal plants used in Japan are producedin the country—the remainder being imported
from China and other countries. “We want toexpand the sources of these ‘second type ofrare-earths’—the first kind being metals such aslithium used in batteries—by working with othercountries,” says Kawahara.
Recently, a research group at RCMPR
produced liquorice root by hydroponic culture—
growing plants using mineral nutrient solutions
in water and without soil. Liquorice root contains
the sweet-tasting compound glycyrrhizin and is
widely used as an herbal medicine, as well as asweetener for food products.
Furthermore, another medicinal plants group
has developed medicinal treatment for Leishmaniasis, a disfiguring disease transmitted by sandflies, based on screening of medicinal plants
in countries including Myanmar, Peru, and theSolomon Islands. “We used the local
knowledge to produce a solution for this disease,” says
Kawahara.

SOCS for Intractable Diseases
Tetsuji Naka is the
project leader of the Immune Signaling Project.
“We need to work on

Advertisement“We hope that our research will enable a reduction in both time and cost of drug
development, as well as the development of safer drugs.”

Nobuo Kawahara
people,” says Naka, “and not [only on] cells or
lab animals. So we are working with colleagues
at the Osaka University Graduate School of
Medicine on the treatment of intractable diseases
such as cancer using SOCS [suppressor ofcytokine signaling] gene delivery.”
SOCS is a family of genes involved in inhibiting
the Janus Kinase/Signal Transducer andActivator of Transcription (JAK/STAT) signaling
pathway. “Abnormal expression of SOCS
molecules can cause dysregulated cytokine
signaling, which leads to the development ofdisease,” says Naka.
Recently, Naka and colleagues found overexpression of SOCS3 in cancer cells to be aneffective new treatment for malignant pleural
mesothelioma—a form of lung cancer causedby exposure to asbestos. This is an importantdevelopment considering that asbestos-relateddiseases are expected to reach a peak inaround 2030.

Predicting the Toxicity of Drugs
Tetsuro Urushidani is project leader of the
Toxicogenomics/Informatics Project, which wasrecently awarded The President’s Prize from the
Science Council of Japan for the development of
new biomarkers for human safety. “This is a large
project involving academia, government, and 13
companies, including Astellas Pharma, Daiichi
Sankyo, and Takeda Pharmaceutical Company,”says Urushidani.
The project has yielded a toxicology database,called the Toxicogenomics Project-Genomics
Assisted Toxicity Evaluation system (or TGGATEs), containing millions of data points
collected by observing in vitro changes in gene
expression following administration of more than

Tetsuro Urushidani
150 drugs. The database can be applied in theearly stages of drug development to predict
toxicity risk and characterize the molecularmechanism of this toxicity, without the need for
expensive animals testing.
“We hope that our research will enable a
reduction in both time and cost of drug development, as well as the development of safer drugs,”
says Urushidani.

Ken Ishii

Treatment of malignant pleural mesothelioma

Vaccines and Innovative Adjuvants
Ken Ishii is the project leader of the Laboratory
for Adjuvant Innovation. He is developing vaccines and their adjuvants—substances added tovaccines to increase the response of the immune
system. Ishii joined NIBIO because he wanted totake his ideas from the lab to real world applications, and “not just write high-impact papers.”“We lack a fundamental understanding of themechanisms by which viral preparations affectthe immune response of the body,” says Ishii. “In
October 2010, we established the Next Generation Adjuvant Research Group to address theseissues.” Notably, the Adjuvant Group includes
members from vaccine manufacturers and venture capital companies.
Recently, Ishii reported on why some influenza
vaccines work better than others, and determined that a rare immune system cell type,plasmacytoid dendritic cells, modulate the effectof inactivated flu virus vaccines, but not live virus
vaccines. “These results highlight the importanceof our research,” says Ishii. “We need a scientificapproach to understanding adjuvants, otherwiseinterest in adjuvant research may dwindle, similar
to the demise of gene therapy with viral vectors,
which saw a dramatic decrease in activity following the death of patients on this therapy.”

Hierarchical clustering of genes and chemicals

MORE INFONational Institute of Biomedical
Innovationwww.nibio.go.jp/english

13

OSAK A IN F O CU S: Excellence in Research

Advertisement"One plus one equals three and a little more" at the
National Cerebral and Cardiovascular Center
The NCVC launches the Research and Development Initiative Center for an integrated approach to translational researchin the 21st century.

T

he National Cerebral and Cardiovascular Center (NCVC) was established in1977 by the Japanese government for
the treatment of cardiovascular disease
and to investigate its causes. “Our founding
fathers had great foresight in setting our mission
as being the treatment of both cerebral and heartdiseases,” says Nobuo Hashimoto, presidentof the center, “because a malfunction of, say, theheart can lead to a stroke due to clogged bloodvessels in the brain.” Invoking a common Japanese expression, Hashimoto further illustrates
the benefit of the center’s broad mission: “Ourintegrated approach to treatment utilizes all our
extensive resources, where one plus one equals
three and a little more.”
The NCVC is internationally renowned for its
scientific contributions, including the discoveryof bioactive peptides such as atrial natriuretic
peptide and brain natriuretic peptide, the development of artificial hearts and lungs, and research
into the rapid treatment of acute cerebral
thrombosis using the thrombolytic drug tissue
plasminogen activator (t-PA) in combination with,or without, catheter procedures.
In April 2010, the Japanese government
reorganized the NCVC into an independent administrative institution, thereby giving Hashimotoand his staff greater autonomy to hire specialists—especially from industry—and initiate new
wide-ranging collaborative research activities.
The NCVC has continued to evolve. “We set
up the Research and Development Initiative
Center (RDIC) in April 2010,” says Yoshiyuki
Taenaka, director of the RDIC. “This center was
set up by the NCVC and offers a one-stop ap-

Nobuo Hashimoto

Yoshiyuki Taenaka

proach for translating basic research and clinical
trials into real-life applications.”
Notable areas covered by the RDIC include
preventative medicine and epidemiologic
informatics, a biological and clinical data bank,and intellectual asset management. “We want toshare our wealth of assets with the public andindustry,” says Taenaka, “including our knowledge of how to prepare healthy diets for patients
suffering from specific ailments. We also haveresearch facilities for drug and medical device trials, which we are willing to share with industry.”
These resources include the NCVC Hospital.
“Our hospital has 640 beds of which about 30
percent are for treatment of diseases requiring
intensive care,” says Hiroaki Naito, director
general of the hospital.
Staff at the RDIC are committed to Director
Taenaka’s vision. “My mission is to support clinical trials,” says Haruko Yamamoto, director,
Department of Advanced Medical Technology
Development. “We are testing drugs for efficacy
against so-called orphan diseases, which large
pharmaceutical companies often ignore because
they are not commercially viable.”
An important mission of the RDIC is the securecollection, storage, and analysis of data on
cardiovascular disease for preventative medicine.
“Clarifying the cause of stroke and cardiovasculardisease is important as a first step in prevention,”says Yoshihiro Miyamoto, director, Departmentof Preventative Medicine and Epidemiologic Informatics. Studies of residents in highly populated

Hiroaki Naito

Kazuo Minematsu

Japanese cities show higher occurrences of heartdisease compared with other Japanese cohorts.
“This reflects the possible effects of modern
urban life in Japan,” says Miyamoto.
When prevention fails, rapid treatment is essential. “We established the first stroke care unit
and earliest coronary care unit in Japan,” says
Kazuo Minematsu, deputy director general of
the NCVC Hospital.
The NCVC multidisciplinary team, including
Takeshi Nakatani, director, Departmentof Transplantation, has made tremendous
contributions to heart transplants and clinicalapplications of the ventricular assist device(VAD) including the NCVC-type, for long-term
circulatory support.
In addition to reducing treatment time during
emergencies, the NCVC is initiating trials of a‘mobile telemedicine’ system that will transmit essential medical data from ambulance tohospital, aiding physicians in their diagnosis prior
to the patient reaching the hospital. Recently,
Hiroshi Nonogi, chairman of the Department of
Cardiovascular Medicine was awarded the first
International Collaboration in Resuscitation Science Award by the American Heart Association,
underscoring the high quality of hyperacute careat NCVC.
But NCVC is not resting on its laurels. “We plan
to integrate the hospital, research laboratories,
and the new RDIC into a single building to create
an environment even more conducive for translational research,” says Hashimoto.

MORE INFONational Cerebral and CardiovascularCenter
www.ncvc.go.jp/english/

14

Haruko Yamamoto

Yoshihiro Miyamoto

Takeshi Nakatani

OSAK A IN F O CU S: Integrating Research and Business

Advertisement

Realizing the Potential for Life Sciencesin OsakaT

he Northern
Osaka
Biomedical
Clusterconsists of an area covering
a 20 km radius, centeredon the Doshomachi district,
Osaka City. The origin of the
district goes back to 17th
century when it became thenational center of pricing anddistribution of raw materials
for herbal medicines.

The cluster was established based on theambitious vision of Yuichi Yamamura, former
president of Osaka University, to make Northern
Osaka a destination for the life sciences.
This vision is now coming to fruition. A significant development was the opening in September 2008 of the Osaka Bio Headquarters at
the Senri Life Science Center building to act asa bridge in coordinating bioscience projects involving academic, industrial, and governmentalorganizations. Additionally, a number of startup
companies have been established in the area,
over 300 Osaka Pharmaceutical Manufacturers Association (OPMA) member companies
are conducting business around Doshomachi,
and world-class research is being carried out
at institutes such as the National Institute of
Biomedical Innovation, the National Cerebral
and Cardiovascular Center, Osaka University,
Osaka Prefecture University, and the National

Saito Life Science Park and Nearby Research Institutes
Institute of Advanced Industrial Science andTechnology (AIST).
In the cluster, the Saito Life Science Park
(LSP) is becoming increasingly important as aplace to conduct biotechnology research andbusiness, with 40 companies and approximately 1,300 researchers and support staff working
on site. Small and medium sized companies
and university startups will be able to expand
their business at the Saito Bio Incubation
Facilities, which include wet labs and animal
research facilities.
Additionally, a new industrial park neighboring
the Saito LSP is scheduled to begin operation in
the spring of 2014. It is expected that innovative
industries, including those in the life sciences,
will move to this area and join those alreadyestablished in the Saito LSP.
To accelerate biotechnology developmentin the Osaka region, an ambitious set of goals

called the Osaka Bio Strategy has been laidout. These goals—including that the Osaka
Bio Cluster should rank at least 5th worldwide
in the biomedical field within 10 years—were
devised by the Osaka Bio Strategic Promotion
Conference, headed by Toru Hashimoto,governor of Osaka, and chaired by Tadamitsu
Kishimoto, former president of Osaka University.
The Osaka Bio Strategic Promotion Conference consists of 10 organizations (listed on
page xv). The policies of the Conference are
implemented by the Osaka Bio Support Group,
made up of 20 members from the front lineof the biotechnology field, led by Isao Teshirogi, president and representative director ofShionogi & Co., Ltd.
In an effort to support startup companies,
the Osaka Bio Strategy made provisions for
the Osaka Bio Fund—¥1.1 billion ($13 million) inassets to provide finance for new continued »15

OSAK A IN F O CU S: Integrating Research and Business“World Medical Polis,
Minnesota” Event in Osaka

Osaka Bio Strategic
Promotion Conference
Member Organizations
Ministry of Economy, Tradeand Industry (METI), Kansai
BureauNational Cerebral andCardiovascular Center
National Institute of

Biomedical Innovation
Osaka Bioscience Institute
Osaka Chamber of Commerceand Industry

Osaka Pharmaceutical

Manufacturers Association
Osaka Prefectural Government
Osaka Prefecture University
Osaka University
Senri Life Science Foundation

MORE INFOOsaka Bio Headquarters
www.osaka-bio.jp/en/

16

Osaka Booth at MD&M in
Minneapolis

ventures in pharmaceutical products and medical devices.
Making the most of another of Osaka’s
advantages—a highly-skilled biotech workforce
from world-class universities—Osaka Bio Headquarters provides human resources matching
programs to introduce postdoctoral researchers and senior specialists to startup companies.
On the clinical side, Osaka Bio Headquartersorganizes the Osaka Clinical Trials website incooperation with OPMA. The website releases
the results of clinical trials run by Osaka’s 13
highly specialized hospitals.
Established in May 2009, the Protein Mall
Kansai (PMK, protein-mall.osaka-bio.jp/en/)
is Japan’s largest assembly of protein-related
research institutes and companies, organizedby the Osaka Bio Headquarters and the Senri
Life Science Foundation.
The 75 members of PMK aim to create
commercial opportunities through the practical application of protein-related research,
the promotion of collaborative research, andthe support of contract research, all of which
contribute to innovative technology and new
business in the Kansai region, which includes
Osaka and five other Prefectures.
The Osaka Chamber of Commerce andIndustry (OCCI) promotes open innovation by
providing business-matching programs. Specific programs include the Drug Seeds Alliance
Network Japan (DSANJ, www.dsanj.jp/e/) with
OPMA as a co-organizer, formed to acceleratetechnology transfer in the following areas: drugcandidates and targets; foods and cosmetics;
biomarkers, diagnostics, and reagents; andplatform technologies.
OCCI maintains the DSANJ database andconducts partnering events categorized by disease area, country, or region. There are already164 organizations networked as technology
providers, and 55 pharmaceutical companies
with a presence in Japan have registered astechnology searchers. DSANJ is active interna-

Institut Pasteur has signed an
MOU with OCCI

tionally, having organized successful meetings for European and Korean companies on
Alzheimer’s disease.
The Medical Device Forum holds regularmonthly meetings where professional
medical researchers and doctors frommedical institutions propose joint projects forindustry to develop, such as medical devices,
biomedical protocols, and equipment. OCCI
conducts the World Forum for BIO/MEDICAL
Device in Kansai for stimulating alliances
between Japanese and overseas companies
in medical device fields. Utilizing the Kansai
region's strengths in developing advanced
medical platforms, these initiatives are seen
as economic models that can be applied
nationwide in the drug discovery and the
medical device industries.

International Partnerships
In February 2010, OCCI signed a memorandumof understanding (MOU) with the Bio Business
Alliance of Minnesota, United States—one of
the top medical device clusters in the world—with the goal of forming an alliance between
Japanese and Minnesota-based companies topromote the development and commercialization of medical devices.
Furthermore, an MOU between OCCI and Institut Pasteur in Paris, France in the field of drug
development was signed June 2010. Institut
Pasteur maintains a presence on the DSANJ
database, posting technology information thatserves to promote alliances with Japanesepharmaceutical companies.
The Kansai Bio Promotion Conference has
also signed MOUs with partners in France, Belgium, and the State of Queensland in Australia.
These alliances are possible because of thehistorical accomplishments of the life sciences
community in Osaka. This community plans tocontinue building upon this strong foundation,
creating greater potential for life science-related
research and business in the future.

Advertisement

Dynamic and Evolutionary Research on Protein Science
The Institute for Protein Research was set up in 1958 as a joint-use research facility of Osaka University and has played a central
role in protein science both in Japan and around the globe.

I“n the early days this institute wasaddressing issues related to nutrition,”says Toshiharu Hase, director of theInstitute for Protein Research (IPR). “NowToshiharu Hase
we conduct fundamental research on proteinscience—P450 was discovered here. We also
clarified the 3D structure governing semaphorin
support the development of the Worldwide
signaling through the plexin receptor. “We used
Protein Database and the Protein Data Bank of
X-ray analysis to determine the 3D structure ofJapan [PDBj, www.pdbj.org].”
Semaphorin 6A and Plexin A2, before and after
The IPR has state-of-the-art research
signal transmission,” says Takagi. “Our discovery
facilities, including equipment for X-ray analysis
will contribute to the understanding of theand a powerful 950 MHz nuclear magnetic
mechanism underlying many serious diseases
resonance spectrometer. There are also plans
and the development of new drugs.” Indeed,
to install a cryo-electron microscope. Notably,
this report resolves the structural mechanism
IPR has a dedicated beamline at the SPring-8
governing receptor activation, namely thesynchrotron facility in Hyogo, which is available
transmission of signals across membranes.
for collaborative research.
Takagi is also conducting research on
IPR has inter-faculty agreements with a number
the structure of proteins that are implicatedof academic institutions, including Peking
in neuronal synapse functions through
University in China, Yonsei University and Seoul
ultrastructural analysis of proteins using electron
National University in South Korea, National
microscopy and tomography.
Tsing Hua University in Taiwan, Indian Institute of“I want to use our know-how to tell the whole
Chemical Biology in India, and the University of
biological story based on the 3D structures ofManchester in the United Kingdom. The instituteproteins,” says Takagi.
also often welcomes international scientists, for
Also interested in structural biology is Akira
example it hosted eight researchers from seven
Shinohara at the Laboratory of Genome andoverseas countries in 2009.
Chromosome Functions, who is investigating
IPR is also the source of new, enabling
the molecular mechanisms of homologous
technologies. Junichi Takagi is a structural
recombination using molecular, genetic, andbiologist at the Laboratory of Protein Synthesis
biochemical methods.
and Expression. “Our group
has developed a highpurity recombinant protein
expression/purification
system for a wide range ofproteins,” says Takagi. “Wehave created an inexpensive
and fast affinity purification
method, which has played avital role in many structural
biology projects.” Recently,
Takagi was the focus of
Akira Shinoharainternational attention when he

Junichi Takagi“Malfunction of homologous recombination
leads to cancer and infertility in humans,” says
Shinohara. “My research interests are to clarify
the mechanism of homologous recombinationin eukaryotes and the mechanism of meiotic
recombination.”
Shinohara is studying the role of protein/genes
in the RAD52 family both in vivo and in vitro, andin particular, researching Rad51—a homolog ofbacterial RecA. Notably, Rad51/RecA is known
to form a right-handed helical filament on singlestranded (ss) DNA and carry out homology
search and strand exchange during the recombination process. Since the Rad51-mediatedexchange event is inefficient in vitro, other factors
must be required to promote this reaction, including Rad52-mediated formation of a ring-likestructure on the ssDNA, which facilitates thebinding of Rad51 to the DNA.
“We are also studying recombination andchromosome dynamics during meiosis—a typeof cell division that occurs during the productionof gametes [eggs and sperm],” says Shinohara.
Recent work has implicated the Csm4 proteinin the specific movement of DNA ends duringrecombination. “Our results imply that chromosome movement promotes a variety of biochemical reactions on chromosomes including meiotic
recombination,” says Shinohara. “More recent
experiments indicate that physical forces may beregulating chromosome functions—that is, physics may regulate biochemistry.”

MORE INFO
Institute for Protein Research,
Osaka University
www.protein.osaka-u.ac.jp

17

OSAK A IN F O CU S: Integrating Research and Business

Excellence in Interdisciplinary Research and Education
Osaka University’s Graduate School of Frontier Biosciences offers a stimulating environment for cutting-edge interdisciplinary
research on biological system dynamics.

MORE INFO
Graduate School of Frontier Biosciences,
Osaka University
www.fbs.osaka-u.ac.jp

18

Keiichi Namba
cryomicroscopy and X-ray diffraction,” says
Namba. “Recently, we used cryomicroscopy tosuccessfully visualize the structure of F-actin ina few days.” F-actin is the helical polymer of aprotein, actin, which is an essential componentof muscle fibers and cell cytoskeletons. These
results offer a deeper understanding of thecellular mechanisms governing life. Namba
is also investigating the source of energy forthe torque of the bacterial ‘flagellar motor’—arotary nanomachine composed of assemblies
of proteins—and how the tiny helical propellers
connected to the rotary motor propel bacteria
through liquids.
Toshio Yanagida, who is the leader of theSoft Biosystems Group at Osaka University
and a pioneer of single molecule imaging, isnow focused on the dynamics of living cells.
“Molecular machines use fluctuations such as
Brownian motion,” says Yanagida. “A deeper
understanding of how living cells use such
fluctuations—or yuragi—to process enormous
amounts of information will enable the design ofmore energy-efficient and robust machines.”
In 2011 and 2012, Yanagida is launching two
major interdisciplinary
projects. One is the
Quantitative andComputational Biology
Center (QBiC), which
begins in April 2011
and aims to develop
a comprehensive
understanding of
biological system
dynamics. “This is amulti-institute project
Toshio Yanagidawith Osaka University

Structure of F-actin and Flagellar Motorand RIKEN,” says Yanagida. “We will focus
on the basic elements regulating biologicalsystems while developing new experimental
and theoretical techniques. The infrastructure
for the project includes a new 7000 square
meter building, 15 principle investigators, 60
postdoctoral researchers, 20 technicians,
and more than 20 graduate students. We
aim to double this manpower by 2013,” says
Yanagida.
The other initiative is the Brain Information
Transmission Interdisciplinary Research Center,to be launched in 2012 in collaboration with the
National Institute for Communication Technology(NICT, in Hyogo) and the Advanced Telecommunications Research Laboratory (ATR, in
Kyoto). “This project focuses on how the brain
processes internal and external information, andhow to transmit this data to a computer. This
could revolutionize human-machine communication and network system technologies,”emphasizes Yanagida. The project is based on
three main pillars: heart-to-heart science (HHS),
brain–machine interface (BMI), and brain-function installed information network (BFI).
The aim of these collaborations is to analyze the flow of
information, energy, and materials within living organisms andinterface them with an external
control system. ”We will startwith single molecules and work
up towards the whole brain,”
explains Yanagida. “Ultimately,such studies are expected tolead to the construction of highly
energy-efficient machines andadvanced medical diagnostics.”

CREDIT: (TOP RIGHT) PROFESSOR KEIICHI NAMBA, OSAKA UNIVERSITYT

he Graduate School of Frontier Biosciences (FBS) at Osaka University wasestablished in 2002. “Our mission is to
educate graduate students in an interdisciplinary environment,” says Keiichi Namba,
dean of FBS. “Our 70 or so faculty members arefrom diverse backgrounds including mathematics, physics, chemistry, medicine, and information
science. And our approximately 250 graduate
students interact with these specialists. It’s aunique graduate school, and very popular withstudents from both Japan and overseas.”
Doctoral students at FBS receive support
from the prestigious Global Center of Excellence(GCOE) program running from 2007 to 2011. Aspart of this program, students spend one month
doing their research in the laboratory of anotherresearch group. “This enables students to gain
firsthand experience in interdisciplinary research,”says Namba.
The graduate school entrance examination at
FBS is flexible, offering applicants the choice ofsitting exams in physics/mathematics, biology, or
chemistry. “We welcome students from overseas
with appropriate TOEFL [test of English as aforeign language] and GRE [Graduate Record
Examination] scores,” says Namba.
In addition, the FBS holds annual symposia,
biannual summer schools, and annual retreats—
which are open to overseas participants—and
supports collaborative visits of students andpostdocs to universities and research institutes
in the United States, Europe, and Asia.
Namba is a biophysicist specializing in
biological nanomachines. “We analyze thestructure and dynamics of macromolecularassemblies using techniques including electron

Advertisement

Pharmaceutical Approach to Alleviating Human Disorders
Scientists at the Graduate School and School of Pharmaceutical Sciences of Osaka University are dedicated to investigatinga range of pharmaceutical and health sciences, including cancer and psychiatric disorders. Here, we talk to two prominent
members devoted to translational research.

K

azutake Tsujikawa is known forthe discovery of prostate cancer
antigen-1 (PCA-1), a gene highly
expressed in prostate cancer
and pancreatic cancer. “Prostate cancer is one of
the biggest killers in the world,” says Tsujikawa.
“We are using mouse models to study whether
this gene can act as a molecular marker, a biomarker, for this type of cancer, which may allow
early diagnosis.”Currently the biological roles of this novel generemain unclear. Tsujikawa and colleagues foundthat in vitro silencing of PCA-1 induced apoptosis
in cancer cell lines and significantly reduced tumor
formation in vivo. They concluded that PCA-1
may serve as a promising molecule target for
prostate cancer and pancreatic cancer therapy.
Tsujikawa has recently developed an enzymebased assay for PCA-1 activity to aid in screening
possible therapeutic agents. “PCA-1 is a memberof the hABH [human AlkB homologs] family,” says
Tsujikawa. “We have also discovered that theexpression of hABH family proteins may correlatewith specific cancers. The hABH family of molecules could be targets for cancer therapy. We
are working on a joint industry-academia-government project to clarify the cancer mechanisms fortranslational research.”
This research is being conducted in collaboration with the medical school of Osaka University,
Nara Medical University, Kagoshima University, and Hyogo University of Health Sciences.
Tsujikawa is also pursuing research as part of the
Ministry of Education, Culture, Sports, Scienceand Technology's Knowledge Cluster Initiative(second stage) and the Program for Promotion of
Fundamental Sciences in Health Sciences of the
National Institute of Biological Innovation.
Tsujikawa is also working on calcitonin generelated peptide (CGRP) that is released fromsensory nerve endings. CGRP is known to playa central role in migraine and diseases such asheart failure. “We have generated mice deficient

Kazutake Tsujikawa
in RAMP-1 [receptor activity modifying protein 1],
a specific subunit of CGRP receptors. Interestingly, RAMP-1-deficient mice showed recovery
from experimental allergic encephalomyelitis. The
result indicates that CGRP plays a crucial rolein controlling the body’s immune system,” says
Tsujikawa. The research is supported by the Japan Chemical Industry Association as part of theInternational Council of Chemical Associations
Long-Range Research Initiative.
Hitoshi Hashimoto is at the Laboratories of
Molecular Neuropharmacology where he investigates the molecular mechanisms for psychiatricdisorders and drugs for their treatment. “We areusing molecular biology and animal models to
identify new molecular targets for the development of drugs,” says Hashimoto.
Hashimoto is investigating the molecular pharmacology of pituitary adenylate cyclase-activating
polypeptide (PACAP); identifying and evaluating
hyperplasia-associated gene of beta cell (HPGB),
regenerating islet-derived protein 3 (RegIII), andprostaglandin receptor CRTH2 as molecular targets for drug discovery; and developing methods
to differentiate embryonic stem cells into neurons.
“In 1993, we successfully cloned the cDNA of
MRI images of diminished tumor growth in PCA1-knockdown prostate cancer cells in a xenograftsystem (left, control; right, PCA-1 knockdown).
The arrow indicates a tumor.

Hitoshi Hashimoto
the PACAP-selective receptor, PAC1, in rat brain,”says Hashimoto. “Since then we have investigated the role of PACAP in the nervous system.”Hashimoto’s research includes in vivo studies
on PACAP signaling, which led to the development of mice lacking the PAC1 receptor gene
and/or PACAP gene and a transgenic mouse line
overexpressing the PACAP gene. Notably, micelacking PACAP (PACAP-/-) exhibited behavioral
abnormalities, including explosive jumping, suggesting that PACAP has a role in the regulation of
psychomotor functions.
Furthermore, clinical genetic experiments
showed variants of the genes encoding PACAP
and PAC1 receptor to be associated with schizophrenia, implicating PACAP-mediated signaling
pathways in psychiatric disorders.
Recently, Hashimoto used PACAP-deficient
mice as a model to study how light intensity
affects resetting of the circadian clock when lightcycles are altered. Intriguingly, PACAP-deficient
mice also showed depression-like behavior,
making them potentially useful for studies on
the mechanistic association between an alteredbiological clock and depression.
Hashimoto’s research has an international
perspective. “I collaborate with David Vaudryat INSERM, France; Herbert Meltzer at the
Vanderbilt University Psychiatric Hospital; Dóra
Reglödi at University of Pécs, Hungary; and manycolleagues elsewhere.”

MORE INFO
Graduate School and School of
Pharmaceutical Sciences, Osaka University
www.phs.osaka-u.ac.jp/en/

19

OSAK A IN F O CU S: Integrating Research and Business

Breaking the Mold: Changing Traditional Views of Dentistry
The Graduate School of Dentistry at Osaka University plans to introduce ambitious new programs for a molecularbiology-based approach to training dentists in the 21st century.

“W

hat is a dentist?” asks
Toshiyuki Yoneda,
dean of the Graduate
School of Dentistry at
Osaka University. “I am afraid that dentistry is
still viewed as a surgical-based vocation involving filling cavities and pulling teeth. We want todestroy this antiquated view because we believethat the future skill sets of dentists must cross
many disciplines, including pharmacology, law,and even the arts.”
The heart of the problem in Japan is the rapidly aging population. “The majority of patients inJapan are middle-aged or above, and traditional
ailments such as tooth decay are no longer themain issues for dentists,” says Yoneda. “For example, periodontal disease in an elderly patient
can be linked to other diseases such as diabetes
and cardiovascular disease, so dentists must beable to understand these other systemic disorders. We must revise the education curricula for
dental schools to include a deeper understanding of molecular biology and pathophysiology.”
Yoneda also says that he wants Osaka
University—a comprehensive university withschools of medicine, pure sciences, engineering,
and arts—to introduce new curricula for training
dentists. As a first step, Yoneda has submitted
a proposal to the Ministry of Education, Culture,
Sports, Science and Technology to establish a
program on ‘Life Innovation’. The six-year program would focus on intractable diseases of themouth and their relationship with other diseasesof the body. Distinctive features of the program
include: the awarding of a Master of Oral Diseases to graduates of a post-residence course,

MORE INFO
Graduate School of Dentistry,
Osaka University
www.dent.osaka-u.ac.jp/english

20

Graduate Schoolof Dentistry

Approach for Periodontal
Tissue Regeneration

introduction of special lectures on ‘biodentistry,’
results showing that teeth weakened bycreation of a personal genome database using
periodontal problems can be made stronger by‘oral bioinformatics,’ and the establishment of an
drug therapy using fibroblast growth factor-2‘intractable diseases international station.’[FGF-2].”
In addition to these plans, Yoneda and his
At the Cell Processing Center, the group led bycolleagues are also involved in cutting-edge
Shinya Murakami, head of the Department ofresearch. Recent highlights include studies
Periodontology, is extracting fat cells to generate
on bone biology in which the researchers
periodontal tissue. “This is the first such center
discovered a link between stress signals inin a dental school in Japan and, although we are
the endoplasmic reticulum (ER)—an important
still in the early stages, we have had encouraging
cellular compartment in which protein folding
results that indicate the possibility of producing
occurs—and activation of vesicular trafficking
periodontal tissue from fat cells,” says Yoneda.
out of the ER.
The Osaka University Graduate School
In an equally high-impact contribution,of Dentistry holds many joint symposia with
Yoneda’s group conducted experiments in anuniversities and institutes in the United States,
attempt to quantify pain. “Pain is a subjective
United Kingdom, Korea, and Thailand. Osaka
experience, but our experiments show promise
students can go to the United States for two–
as a means of producing an objective view,” says
month ‘home stays’ to improve their English.
Yoneda. Experiments on inflammatory pain in
The dental school holds regular community
rats showed the importance of proton sensing
outreach forums to emphasize the importance
receptors, such as TRPV1, in the transmission ofof dentistry, and its evolution, for the young
pain. When activated,and old.
Surgery at the Translational
TRPV1 appears to
Osaka University was
Research Center
upregulate calcitonin
the first governmentgene-related peptide
run comprehensive(CGRP) expression, auniversity to establish a
scenario associatedschool of dentistry. “Wewith inflammatory
pioneered dentistry in
pain.
Japan,” says Yoneda.
“We have also been
“I am confident that ourworking on using
new initiatives based
drugs to treat oral
on a molecular biology
diseases, instead of
approach will inspire
periodontal surgery,”education and researchsays Yoneda. “Weat dental schools inhave convincing
Japan and globally.”Advertisement

Evolution from Molecular Biology to Atomic Biology
Seiki Kuramitsu believes that thermophilic bacteria, which live in water temperatures close to boiling, offer an excellent model for
creating a new system biological field of life sciences that predicts biological function through atomic-level analysis.

I“n spite of the tremendous advances in
the life sciences, it is still not possible toaccurately predict the results of medical
treatment,” says Seiki Kuramitsu,
professor in the Department of Biological
Sciences, Graduate School of Science, Osaka
University. This department was established in1949 for education and research in the biologicalsciences, based on advances in science at theboundary of chemistry and physics. “I believethat it is necessary to construct a new field of life
science whereby we can predict the response ofan organism based on chemistry.”
Kuramitsu's laboratory and many researchgroups are investigating whether biologicalphenomena underlying different environmental
stimuli can be defined in single cells bystudying the 3D structure and function of all
the intracellular molecules at an atomic level.

Seiki Kuramitsu“Thermus thermophilus HB8, an extremely
thermophilic bacterium that thrives at 80ºC, isan excellent model for structural and functional
studies. Its constituent proteins are stable,
and most of its approximately 2,200 genes arecommon to many other organisms, including
humans,” says Kuramitsu.

The four aspects required for understanding
the whole cell system are: (1) structural
genomics, (2) functional genomics, (3) functional
analysis of each system, and (4) simulation andprediction of all biological phenomena in the cell.
“The goal of our so-called Whole Cell Projectis prediction, as opposed to explanation,” says
Kuramitsu. “I want to move from molecularbiology to atomic resolution biology.”“This is a human project, not just an Osaka
project,” adds Kuramitsu. “Also, this is not a
subject just for medical school researchers; it
is an interdisciplinary subject. We welcome theworld’s scientists to join us.”

MORE INFOThe Whole Cell Project
www.thermus.org/e_index.htm

Cognitive Neuroscience Robotics at Osaka
Osaka University launches an innovative program in cognitive neuroscience robotics, supporting
education and development of technology at the human-machine interface.

T

he goal of the Global Center of
Excellence Program (GCOE) basedon cognitive neuroscience robotics
is to develop new information androbot technology systems to provide informationand services based on cognitive neuroscience.
“This highly competitive five-year GCOE
program was launched in 2009,” says Hiroshi
Ishiguro, leader of the program. “I believe that
we were awarded the project because of ourinterdisciplinary approach towards cognitive
science and robotics.”
The project involves experts from robotics,
neuroscience, and human sciences. “Cognitive neuroscience is related to meta-level brain
functions such as memory and reasoning,” says
Ishiguro. “Conventional information and robot
technology, IRT, has produced a more convenient world but without regard for effects on our
cognitive functions. We want to establish newparadigms based on cognitive neuroscience forsafe and adaptable IRT systems.”
One of the goals of the program is to establish
a new graduate school department for students
to study cognitive neuroscience robotics. “There
are many hurdles to overcome to achieve thisgoal, with the highest being the need to scrap
old and low-performing research areas,” says
Ishiguro. “The big question is whether Osaka
University can do this.”
The research and educational activities of the
GCOE program are coordinated with the Advanced Telecommunications Research InstituteInternational (in Kyoto) and the National Instituteof Information and Communications Technology (in Hyogo) in Japan, and institutes overseas
including the Italian Institute of Technology andBielefeld University in Germany.
“We welcome doctoral candidates fromoverseas to join us to create human-friendly
robots based on cognitive neuroscience,”says Ishiguro.

Professor Hiroshi Ishiguro
and his Android“We welcome doctoral candidates
from overseas to join us to createhuman-friendly robots based on
cognitive neuroscience.”

MORE INFO
Global COE Program “Center of
Human-friendly Robotics Basedon Cognitive Neuroscience”
www.gcoe-cnr.osaka-u.ac.jp/english/

21

OSAK A IN F O CU S: Integrating Research and Business

Innovative Approaches to Neuroscience and Microfluidics
AIST Kansai continues to excel in producing ideas for a sustainable society of the future.

T

he National Institute of Advanced
Industrial Science and Technology(AIST) is one of Japan’s largest publicresearch organizations with about
3,000 researchers working at nine locations
throughout Japan.
Takahisa Taguchi is the director of AIST
Kansai. “Our activities here are focused on threeareas: energy, life sciences, and information communications technology,” says Taguchi. “One ofour main goals is to commercialize our research
for the benefit of society.”
Researcher Hidenori Nagai is focusing
on creating compact analytical devices using
microfabrication technology. “I am working ontechnology for the rapid and highly sensitive
detection of target genes,” explains Nagai. “Ihave developed a new method for detecting
DNA based on rapid amplification.” Comparedwith amplification by polymerase chain reaction(PCR), which can take several hours, Nagai’s
approach enables DNA amplification in just
two to five minutes. “This is the fastest method
reported to date,” says Nagai. “Our compact
and fast approach will enable point of caretesting [POCT] on a tailor-made basis.” Nagai
is collaborating with academia to develop acommercial POCT system for genome assays.
The new high-speed PCR system consists ofa pressure sensitive polyolefin film and cycloolefin polymer substrate containing microfluidic
channels. During operation, the device is placed
onto heated aluminum blocks maintained at
95°C (denaturation), 72°C (extension), and 55°C
(annealing). When the sample is injected into
the device, differences in vapor pressure due tothe thermal gradient generate sufficient driving

MORE INFONational Institute of Advanced Industrial
Science and Technology (AIST), Kansai
www.aist.go.jp/index_en.html

22

Hidenori Nagai
forces to move droplets of the sample throughthe various zones in the microcapillary network.
“We successfully used this device to detect
anthrax down to a concentration of 10 cells per
microliter after a five-minute amplification,” says
Nagai.
Masami Kojima is studying the effect ofbrain-derived neurotrophic factor (BDNF) on
brain function. “In 2003, I was with the group at
the National Institutes of Health [in the UnitedStates] that identified BDNF as playing a rolein memory formation,” says Kojima. “We foundthat a common polymorphism [Val66Met] inthe BDNF gene affects human memory and thesecretion mechanism of the growth factor.”More recently, Kojima and colleagues reported
that BDNF regulates cholesterol synthesis forsynapse development. Specifically, they showed

Masami Kojima

Microfluidic Device for High-Speed PCRthat BDNF induces de novo cholesterol biosynthesis in cultured cortical and hippocampal
neurons, thereby indicating a role for BDNF incholesterol metabolism.
“Depression is a serious illness affecting millions of people worldwide, and BDNF may havea role to play,” says Kojima. “So, recently I havebeen working with clinicians on a national project[JST/CREST] on mental illnesses—including
depression—focused on molecular dysfunctionof BDNF.”
Kojima works with many groups overseas,
including those in the United States and China.
“One of the major goals of AIST is to find applications for our research,” says Kojima. “I often
discuss my work with colleagues at AIST and atother institutes to achieve this goal, which would
be difficult to accomplish by myself.”Advertisement

Cancer Research at Osaka Prefecture University
Five contrasting and innovative approaches to diagnosing and curing cancer.

Osaka Prefecture University(OPU) is one of the largest
public universities in Japan.
Established about 130 years
ago to train veterinarians, the university employs
707 faculty who teach the approximately 8,000
students—164 from overseas—attending classes at three campuses: Nakamozu, Habikino,
and Rinku.
Here, we introduce the research activities offive members of the OPU faculty who are actively
involved in the Osaka Prefecture University Bio
Strategy Committee on the development of bioindustries in the Osaka Bay area.
Kikuya Sugiura, a veterinarian at the Schoolof Life and Environmental Sciences explains his
research: “I am developing immunology-based
therapy for tumors using dendritic cells [DC].
The function of DC is to present antigens to T
lymphocytes, activating the immune response.
We are obtaining these cells in culture by inducing the differentiation of monocytes isolated fromblood, which can then be used to fight cancers.”
This method alone, however, is not effective
in completely destroying tumors. In a novel
approach, Sugiura injects interferon γ (IFNγ)—apotent inducer of the T lymphocyte-mediatedimmune response—along with DC into dogs
with naturally occurring tumors, brought to
the OPU veterinary school for cancer therapy.
“This treatment induced complete healing in thedogs,” says Sugiura. “They are an almost perfectmodel for these experiments because breast
cancer, lymphoma, and osteosarcoma occur
spontaneously. So if the treatment is effective indogs, there is a very high probability that it will
work in humans.”
Sugiura is also testing drug delivery directly
into the tumor microenvironment by introducing
cytokine genes into tumor cells using a genedelivery system. Applying IFNγ and DC together
appears to create a strong synergistic immune
response against tumors, providing hope for the

Kikuya Sugiuradevelopment of a similar treatment in humans.
Using dendritic cells (DC) developed from peripheral
Ikuo Fujii, based at the Graduate School ofblood monocytes (Mo) by granulocyte-macrophage
Science, is an active member of the Osaka Precolony stimulating factor (GM-CSF) and interleukin
fecture Bio Strategy Committee and is commit(IL)-4, DC-based immunotherapy has provoked
ted to making Osaka a center for life sciences.
immune responses against cancer in humanFujii has recreated in the laboratory the process
patients. However, improvements are necessary
by which the immune system makes antibodies
in order for the immune response to be sufficientand is developing low molecular weight peptides
for a satisfactory clinical outcome. Interferonknown as microantibodies. This will allow him to
gamma (IFNγ), a potent inducer for DC maturation“contribute to molecular–targeted medicine andand T helper type 1 response, is an important tool
advanced medical diagnostics,” says Fujii.
for achieving such improvements. Inoculation of
In particular, Fujii is addressing problems assocanine IFNγ with DC into the microenvironment of
ciated with antibody medicine. These problems
canine tumors significantly improved the clinicalinclude antigenicity, manufacturing costs, andoutcome, including complete remission of mammarycell membrane permeability issues. “I am reprocarcinomas. For obtaining local-limiting and longducing the functions of antibodies using smalllasting effects of IFNγ, methods are being developed
peptides,” says Fujii. “I have developed a uniquefor in vivo transfection of the canine IFNγ gene into
phage-display peptide library of peptide surtumor cells using a gene delivery system (GDS).
faces, which are stable against proteases in the
Results from the study of dogs with common humanblood, show high binding activity and specificity,
tumor types may provide useful information for theand are highly membrane permeable.” Thesedevelopment of human cancer therapies.
exciting results are expected tocontribute to the development of the
MRI-detectable dendron
thermosensitive polymer
biocompatible polymer
next generation of antibody-based
therapeutics and diagnostics for thedetection and treatment of cancer.
The precise and reproducibledelivery of bioactive molecules
to specific targets is essential
for the development of medical
Detection of liposome
treatment protocols. Chemist Kenjiaccumulation with MRI
Kono is developing biofunctional
nanomaterials for the deliveryof drugs to treat cancer. “Thedevelopment of accurate drugdelivery technology is critical for
personalized chemotherapy,” continued »Detection of liposome accumulation of mouse tumor with MRI

23

OSAK A IN F O CU S: Integrating Research and Business

Advertisement“We are aiming to lead research in the field of high-precision, liposome- anddendrimer-based drug delivery.”says Kono. “We are aiming to lead researchin the field of high-precision, liposome- anddendrimer-based drug delivery.”In one set of experiments, Kono andcolleagues loaded anticancer drugs into
temperature-sensitive 100 nm-diameter
liposome capsules that are designed tobreak down at elevated temperatures. They
injected the capsules into a tumor, appliedan RF microwave to locally heat the capsule
to about 45°C, and monitored the deliveryof the anticancer drugs using magnetic
resonance imaging. “Having a way to visibly
monitor the delivery, release, and spread ofdrugs is important for the development of safe
procedures,” says Kono. Other drug delivery
systems developed by Kono and his teaminclude nanoparticles made up of dendrimers,
artificially-created branched molecules, thatcan respond to stimuli by virtue of surface
modifications or loading of gold nanoparticles.
These can be used for stimulus-induced drug
release or heat generation upon laser lightirradiation. Kono also created drug-carrying
liposomes composed of a new type offunctional, dendron-bearing lipid.
Boron neutron capture therapy (BNCT) is ahigh-energy physics approach to cancer therapy
that combines two treatments that individuallyare virtually harmless, but together can be lethal.
A beam of low-energy (or thermal) neutrons
directed at a tumor interacts with boron-10
isotopes injected into the patient and targeted
to tumor cells using specialized antibodies. “Thisinteraction produces boron-11 particles, which
rapidly decay to produce alpha particles andlithium-7 ions,” says OPU’s Mitsunori Kirihata.
“This reaction is local and destroys cancer cells
without harming adjacent healthy ones.”
Kirihata has developed a method for themass production of highly concentrated
boron-10 compounds (in collaboration withlocally-based Stella Chemifa Corporation), as
well as the synthesis of boron-10-antibody
compounds, which can be injected into patientsand directed to specific tumor sites. Kirihata isalso investigating further applications of BNCT
by developing a new method for synthesizing
fluoride-labeled boronophenylalanine that can

24

Ikuo Fujii
be used in positron emission tomography
imaging of BNCT-treated tumors.
“We have set up a consortium to make the
Osaka Bay Area an international center for
BNCT research and treatment,” says Kirihata.
“The new, compact, and relatively inexpensive
accelerator for BNCT at Kyoto University is amajor step towards the proliferation of BNCT
treatment.”
The drug development process is both time
consuming and expensive, with many compounds being shelved during early testing due
to difficulties in handling, and in many cases
because the compound is simply not sufficiently
soluble in water. These unused compounds
could be potentially useful therapies if modified
to improve solubility and therefore more easily
reach target cells. Takashi Inui at the Graduate
School of Life and Environmental Sciences hasdeveloped a new method of drug delivery thatmakes use of previously abandoned therapeutic
compounds. “I spent many years in the pharmaceuticals industry and am aware of the vast number of unused compounds,” says Inui. “I havesuccessfully loaded low-solubility drugs inside
L-PGDS [lipocalin-type prostaglandin D synthase]carrier cavities. I call this a drug delivery system
based on intelligent-type artificial proteins.”
The drug molecules exhibit selective
molecular biorecognition and can be used
for targeting cancer tissues. Inui used mass
spectroscopy, SAXS (small-angle X-ray
scattering), and NMR to identify that the drug
was indeed inside and bound to the carrier
capsule. “This is a world first, and I expect theseresults will have a tremendous effect on drug
discovery,” says Inui.

Takashi Inui

Kenji Kono

Mitsunori Kirihata

MORE INFOOsaka Prefecture University
www.osakafu-u.ac.jp/english/index.html

OSAK A IN F O CU S

AAAS/Science would like to express our appreciation andthanks to the following sponsors of this booklet:

AIST Kansai, National Institute of Advanced Industrial
Science and Technology
Graduate School of Dentistry, Osaka University
Graduate School of Engineering Science,
Osaka University
Graduate School of Frontier Biosciences,
Osaka University
Graduate School of Medicine, Osaka University
Graduate School of Pharmaceutical Sciences,
Osaka University
Graduate School of Science, Osaka University
Immunology Frontier Research Center (IFReC),
Osaka University
Institute for Protein Research, Osaka University
National Cerebral and Cardiovascular Center
National Institute of Biomedical Innovation
Osaka Bio Headquarters(Osaka Prefectural Government)
Osaka Prefecture University
Research Institute for Microbial Diseases,
Osaka University
Senri Life Science Foundation

1200 New York Ave., NW
Washington, DC 20005

26© 2011 by The American
Association for the
Advancement of Science.
All rights reserved.